Polar Asset Management Partners Inc. bought a new position in shares of Avanos Medical, Inc. (NYSE:AVNS - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 751,639 shares of the company's stock, valued at approximately $18,701,000. Polar Asset Management Partners Inc. owned about 1.60% of Avanos Medical as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. EverSource Wealth Advisors LLC lifted its stake in shares of Avanos Medical by 132.6% during the 4th quarter. EverSource Wealth Advisors LLC now owns 2,496 shares of the company's stock worth $28,000 after purchasing an additional 1,423 shares during the period. Russell Investments Group Ltd. increased its stake in Avanos Medical by 969.3% in the second quarter. Russell Investments Group Ltd. now owns 2,545 shares of the company's stock valued at $31,000 after purchasing an additional 2,307 shares during the last quarter. Longfellow Investment Management Co. LLC acquired a new position in Avanos Medical in the second quarter valued at $75,000. Wexford Capital LP purchased a new position in Avanos Medical during the third quarter worth about $70,000. Finally, Tower Research Capital LLC TRC boosted its stake in Avanos Medical by 433.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,257 shares of the company's stock worth $77,000 after buying an additional 5,083 shares during the last quarter. 95.17% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
AVNS has been the topic of several research analyst reports. Weiss Ratings reissued a "sell (d-)" rating on shares of Avanos Medical in a research report on Monday, July 20th. Zacks Research upgraded shares of Avanos Medical from a "strong sell" rating to a "hold" rating in a report on Friday, June 5th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Avanos Medical presently has an average rating of "Reduce".
Check Out Our Latest Stock Analysis on AVNS
Avanos Medical Stock Performance
Shares of AVNS stock opened at $24.99 on Wednesday. The company has a current ratio of 2.48, a quick ratio of 1.40 and a debt-to-equity ratio of 0.11. The company has a market cap of $1.17 billion, a PE ratio of -15.52 and a beta of 1.57. The company's fifty day simple moving average is $24.96 and its 200-day simple moving average is $21.22. Avanos Medical, Inc. has a 52 week low of $9.30 and a 52 week high of $25.49.
Avanos Medical Company Profile
(
Free Report)
Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company's products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.
In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.
Read More
Want to see what other hedge funds are holding AVNS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Avanos Medical, Inc. (NYSE:AVNS - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Avanos Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avanos Medical wasn't on the list.
While Avanos Medical currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
